ROIV Stock — Roivant Sciences Ltd.

Roivant Sciences Ltd. (ROIV)

Updated October 16, 2026.

ROIV is a Stock. Total return is 222.4% over the past 5.9 years, 98.8 points ahead of SPY at 123.6%.

Roivant Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for autoimmune and inflammatory diseases, with lead programs including mosliciguat for pulmonary hypertension associated with interstitial lung disease and several monoclonal antibody candidates targeting conditions like thyroid eye disease and rheumatoid arthritis. The company does not currently distribute to shareholders. This security appeals primarily to investors seeking exposure to early-stage drug development and biotechnology innovation rather than income generation.

ROIV performance versus SPY

Price and return data through 2026-10-16.

Total return is 222.4% over the past 5.9 years, 98.8 points ahead of SPY at 123.6%. Over the past year its total return — price change plus distributions reinvested — is 96.0%. Its deepest 1-year drawdown was 20.2%.

ROIV key facts

Asset type

Stock

Asset class

Equity

Inception date

12/08/2020

Distribution frequency

None

Last close

$33.53 (as of 2026-10-16)

Market cap

$24,219,490,693

Average volume

4923438.0

Beta

1.103

Payout ratio

0.0%

EPS

$-0.51

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ROIV risks and drawbacks

The deepest 1-year drawdown on record here is 20.2%.

Who may consider ROIV — and who may not

It is a weaker fit for investors who need monthly cash flow (ROIV does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ROIV

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions